- Apogee Therapeutics (APGE, Financial) will discuss 16-week data from their Phase 2 APEX trial of APG777 on July 7, 2025.
- The trial focuses on patients with moderate-to-severe atopic dermatitis and other inflammatory conditions.
- The webcast is accessible via the company's website, with a replay available post-presentation.
Apogee Therapeutics, Inc. (APGE), a clinical-stage biotechnology company, announced that it will host a conference call and webcast on July 7, 2025, at 8:00 a.m. ET. The event is set to discuss 16-week data from Part A of the Phase 2 APEX trial of APG777, a treatment candidate for moderate-to-severe atopic dermatitis, asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD).
The live webcast will be accessible through the Investors section of Apogee's website. Investors and interested parties can view the webcast at Apogee therapeutics - Events. A replay will be available following the presentation, allowing stakeholders to access key findings at their convenience.
Apogee Therapeutics focuses on developing novel biologics aimed at providing differentiated efficacy and dosing in large inflammatory and immunology (I&I) markets. The company's development of APG777 represents its commitment to addressing unmet needs in conditions like atopic dermatitis, one of the largest and least penetrated I&I markets.
